Developer docs
API playgroundTry for free, no card

Search company profiles

Nexelis

Full company profile

uuid0006ob1

Namestring
Nexelis
Legal namestring
IQVIA
Websiteurl
nexelis.com
Company typeenum
Private
Founded yearint
1989
Descriptiontext

Nexelis is a Seattle, United States-headquartered specialty laboratory services company founded in 1989 and currently operating as a portfolio company of Ampersand Capital Partners. The firm focuses on assay development and advanced laboratory testing, serving pharmaceutical and biotechnology customers with scientifically demanding testing workflows. Its core offering is built around developing and running complex bioanalytical and immunology assays that support vaccine and biologics development programs, leveraging a workforce of 101-250 employees and a founder-led technical leadership team (Founder/CTO Sofie Pattijn, CEO and President Benoit Bouche, CFO Vahé Kalusyan).

Nexelis generates revenue through professional-services laboratory engagements with biopharma sponsors; no public pricing details or customer logos were disclosed in the available data, but the B2B enterprise go-to-market model is implicit in the company's service offering. The company has pursued an inorganic growth strategy, completing two undisclosed bolt-on acquisitions in 2020 — ImmunXperts (March 2020) and AIT Bioscience (July 2020) — to broaden its immunology and bioanalytical assay capabilities. As a PE-backed private company with no disclosed revenue, funding history, or customer concentration data, visibility into financial performance and customer mix is limited; the analysis below flags these gaps rather than imputing values.

Short descriptiontext

Nexelis is a Seattle-based, Ampersand Capital Partners-backed specialty laboratory services company founded in 1989 that provides assay development and advanced laboratory testing for pharmaceutical and biotechnology sponsors, with 101-250 employees.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
101–250
akta.pro rankint
HeadquartersSeattle, United States
HQ citystring
Seattle
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Keyword5 values
assay development services, immunogenicity testing, vaccine laboratory testing, bioanalytical assay services, clinical immunology testing
Industry4 codes
1Companion Diagnostics (CDx) Development & Trial Testing Support
CodeHLAGAEAJPrimaryYes
2Bioanalytical Testing (PK/ADA/NAb)
CodeHLAGADAAPrimaryNo
3Clinical Biomarker Testing Services (central labs, trial enrollment/monitoring assays)
CodeHLAAAMACPrimaryNo
4Companion Diagnostic (CDx) Co-Development Services (biopharma partnerships, clinical strategy)
CodeHLAAAMABPrimaryNo
NAICS code4 codes
  • Medical Laboratories621511
  • Medical and Diagnostic Laboratories62151
  • Medical and Diagnostic Laboratories6215
  • Research and Development in Biotechnology (except Nanobiotechnology)541714
SIC code3 codes
  • Services-Medical Laboratories8071
  • In Vitro & In Vivo Diagnostic Substances2835
  • Services-Commercial Physical & Biological Research8731
Product category
Clinical Laboratory Services
Social media profiles1 record
GTM motion1 record

Each record includes

Type, Description, Source

Revenue model1 record
1Laboratory Services
TypeProfessional Services
Description

Provides comprehensive central laboratory services, specialty biomarker services, bioanalytical laboratories, clinical genomics, and vaccine laboratory services to pharmaceutical and biotechnology companies conducting drug discovery and development.

labs.iqvia.com
Marketing channels3 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels1 record

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components5 values
Personnel, Operations, Infrastructure, Technology or R&D, Marketing or Sales
GTM typeB2B
B2B
Offering typeServices
Services
Core offering1 text field

Nexelis is a specialty contract research organization that develops and validates bioanalytical, immunogenicity, and vaccine assays, then performs advanced laboratory testing on behalf of pharmaceutical and biotechnology sponsors. The offering spans assay development, method validation, and clinical-sample testing across immunology-focused programs, with depth reinforced by the AIT Bioscience bioanalytical and ImmunXperts immunology acquisitions.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 value
  • Streamlined clinical trial workflows through Site Lab Navigator e-Requisition innovation
Product and service5 records
1Assay Development Services
CategoryAssay Development
Description

Custom assay design, development, and validation for pharmaceutical and biotechnology sponsors, with specialization in immunology, immunogenicity, and vaccine-related biomarkers. Delivered as a contracted laboratory service supporting preclinical and clinical-stage programs.

2Bioanalytical Laboratory Testing
CategoryBioanalytical Services
Description

Quantitative bioanalytical testing for small and large molecules using LC-MS and ligand-binding assay platforms, supporting pharmacokinetic, pharmacodynamic, and biomarker analyses. Capability set expanded by the AIT Bioscience acquisition (2020-07-22).

3Immunogenicity Testing Services
CategoryImmunology Services
Description

Anti-drug antibody (ADA) assays, neutralizing antibody assays, and cell-based immunogenicity assessments for biologics and vaccine candidates. Capability set deepened by the ImmunXperts acquisition (2020-03-04).

4Vaccine Laboratory Services
CategoryVaccine Testing Services
Description

Specialized vaccine-focused laboratory services including vaccine immunogenicity testing, characterization, and assay development supporting vaccine developers from preclinical through clinical stages.

5Biomarker Assay Services
CategoryBiomarker Services
Description

Specialty biomarker assay development and testing for clinical development programs, including flow cytometry-based and cell-based biomarker endpoints used in immunology and immuno-oncology trials.

Scale indicator1 record

Each record includes

Type, Value, Description, Source

Partnership1 partner
1OracleBio
Strategic tierCoreTypeTechnology or Integration
Description

Strategic collaboration to advance AI-driven digital pathology. IQVIA Laboratories integrates OracleBio's advanced AI image analysis capabilities to enhance digital pathology workflows and improve clinical insights for customers.

Recent move2 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight2 records

Each record includes

Type, Description

Peers10 records
1ICON plc (ICON Central Laboratories)
TypeDirect peer
Description

ICON operates a global central laboratory network providing biomarker, bioanalytical, and specialty testing for clinical trials — directly overlapping Nexelis's core central lab and specialty biomarker services for pharma/biotech sponsors.

2Fortrea (formerly Labcorp Drug Development)
TypeDirect peer
Description

Fortrea is a leading CRO with a large central laboratory business spun out of Labcorp; it competes directly with Nexelis on global central lab, bioanalytical, and specialty biomarker services for clinical development.

3PPD (Thermo Fisher Scientific)
TypeBroad incumbent
Description

PPD, the clinical research services arm of Thermo Fisher, offers global central laboratory and bioanalytical services as part of a much broader life sciences tools and CRO platform — directly competing with Nexelis at the lab services layer.

4Charles River Laboratories
TypeDirect peer
Description

Charles River provides research models, safety assessment, and laboratory services including bioanalytical and biomarker work for pharma and biotech — directly comparable to Nexelis's discovery, bioanalytical, and vaccine lab service offerings.

5Eurofins Scientific
TypeBroad incumbent
Description

Eurofins is a global laboratory services group with deep pharma/biopharma testing and bioanalytical capabilities across central labs and specialty assays, competing for many of the same clinical trial and discovery sciences engagements as Nexelis.

6BioAgilytix Labs
TypeDirect peer
Description

BioAgilytix is a specialized bioanalytical and biomarker CRO serving large and small molecule drug developers — directly comparable to Nexelis's bioanalytical and biomarker services targeting the same biopharma customer base.

7Q² Solutions
TypeDirect peer
Description

Q² Solutions is a clinical trial laboratory services joint venture with global central lab and biomarker capabilities, directly competing with Nexelis in central lab, genomics, and specialty biomarker testing for clinical development.

8Medpace
TypeBroad incumbent
Description

Medpace is a mid-sized clinical CRO operating its own central laboratory and supporting services for biopharma sponsors, representing a directly comparable operational model to Nexelis with broader therapeutic and geographic reach.

9Frontage Laboratories
TypeDirect peer
Description

Frontage provides bioanalytical, CMC, and clinical laboratory services to pharma and biotech — directly comparable to Nexelis's bioanalytical and biomarker offerings with overlapping small/large molecule and biomarker testing capabilities.

10Syneos Health (now private)
TypeDirect peer
Description

Syneos Health was a global CRO with clinical and bioanalytical laboratory capabilities serving pharma/biotech, directly comparable to Nexelis's clinical development and lab services scope before its take-private transaction.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat2 records

Each record includes

Type, Details

Key risks5 records

Each record includes

Headline, Details, Source

Key highlights6 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Segment3 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile2 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
No
API detail
Has APIbool
No

Docs URL, Description

Integration1 record

Each record includes

Title, Type, Description, Source

AI capability3 records

Each record includes

Type, Description, Source

AI maturity
App detail

Has app

Feature2 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles3 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A2 records

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Nexelis

Clinical Laboratory Servicesnexelis.com

Nexelis is a Seattle-based, Ampersand Capital Partners-backed specialty laboratory services company founded in 1989 that provides assay development and advanced laboratory testing for pharmaceutical and biotechnology sponsors, with 101-250 employees.

What Nexelis does

Nexelis is a Seattle, United States-headquartered specialty laboratory services company founded in 1989 and currently operating as a portfolio company of Ampersand Capital Partners. The firm focuses on assay development and advanced laboratory testing, serving pharmaceutical and biotechnology customers with scientifically demanding testing workflows. Its core offering is built around developing and running complex bioanalytical and immunology assays that support vaccine and biologics development programs, leveraging a workforce of 101-250 employees and a founder-led technical leadership team (Founder/CTO Sofie Pattijn, CEO and President Benoit Bouche, CFO Vahé Kalusyan).

Nexelis generates revenue through professional-services laboratory engagements with biopharma sponsors; no public pricing details or customer logos were disclosed in the available data, but the B2B enterprise go-to-market model is implicit in the company's service offering. The company has pursued an inorganic growth strategy, completing two undisclosed bolt-on acquisitions in 2020 — ImmunXperts (March 2020) and AIT Bioscience (July 2020) — to broaden its immunology and bioanalytical assay capabilities. As a PE-backed private company with no disclosed revenue, funding history, or customer concentration data, visibility into financial performance and customer mix is limited; the analysis below flags these gaps rather than imputing values.

Nexelis firmographics

Firmographics
Name
Nexelis
Legal name
IQVIA
Website
https://nexelis.com
Company type
Private
Founded year
1989
Operating status
Operating
Headcount range
101–250 employees
Short description
Nexelis is a Seattle-based, Ampersand Capital Partners-backed specialty laboratory services company founded in 1989 that provides assay development and advanced laboratory testing for pharmaceutical and biotechnology sponsors, with 101-250 employees.
Ownership category
akta.pro rank

Nexelis industry classification

Industry
Product category
Clinical Laboratory Services
NAICS
Medical Laboratories (621511), Medical and Diagnostic Laboratories (62151), Medical and Diagnostic Laboratories (6215), Research and Development in Biotechnology (except Nanobiotechnology) (541714)
SIC
Services-Medical Laboratories (8071), In Vitro & In Vivo Diagnostic Substances (2835), Services-Commercial Physical & Biological Research (8731)
akta.pro primary industry
Companion Diagnostics (CDx) Development & Trial Testing Support (HLAGAEAJ)
akta.pro secondary industries
Bioanalytical Testing (PK/ADA/NAb) (HLAGADAA), Clinical Biomarker Testing Services (central labs, trial enrollment/monitoring assays) (HLAAAMAC), Companion Diagnostic (CDx) Co-Development Services (biopharma partnerships, clinical strategy) (HLAAAMAB)

Keywords

  • Assay development services
  • Immunogenicity testing
  • Vaccine laboratory testing
  • Bioanalytical assay services
  • Clinical immunology testing

Where Nexelis is headquartered

Location

Headquarters

HQ city
Seattle
HQ country
United States
HQ region
North America

Markets served

Nexelis business model

Business model
GTM type
B2B
Offering type
Services
Cost components
Personnel, Operations, Infrastructure, Technology or R&D, Marketing or Sales

Revenue model

  1. Laboratory Services: Provides comprehensive central laboratory services, specialty biomarker services, bioanalytical laboratories, clinical genomics, and vaccine laboratory services to pharmaceutical and biotechnology companies conducting drug discovery and development.

Go-to-market motion1 record

Distribution channels1 record

Marketing channels3 records

Nexelis product offering

Product offering

Core offering

Nexelis is a specialty contract research organization that develops and validates bioanalytical, immunogenicity, and vaccine assays, then performs advanced laboratory testing on behalf of pharmaceutical and biotechnology sponsors. The offering spans assay development, method validation, and clinical-sample testing across immunology-focused programs, with depth reinforced by the AIT Bioscience bioanalytical and ImmunXperts immunology acquisitions.

Differentiator

Problem solved

Functional benefit

Products and services

  • Assay Development Services Custom assay design, development, and validation for pharmaceutical and biotechnology sponsors, with specialization in immunology, immunogenicity, and vaccine-related biomarkers. Delivered as a contracted laboratory service supporting preclinical and clinical-stage programs.
  • Bioanalytical Laboratory Testing Quantitative bioanalytical testing for small and large molecules using LC-MS and ligand-binding assay platforms, supporting pharmacokinetic, pharmacodynamic, and biomarker analyses. Capability set expanded by the AIT Bioscience acquisition (2020-07-22).
  • Immunogenicity Testing Services Anti-drug antibody (ADA) assays, neutralizing antibody assays, and cell-based immunogenicity assessments for biologics and vaccine candidates. Capability set deepened by the ImmunXperts acquisition (2020-03-04).
  • Vaccine Laboratory Services Specialized vaccine-focused laboratory services including vaccine immunogenicity testing, characterization, and assay development supporting vaccine developers from preclinical through clinical stages.
  • Biomarker Assay Services Specialty biomarker assay development and testing for clinical development programs, including flow cytometry-based and cell-based biomarker endpoints used in immunology and immuno-oncology trials.

Quantifiable outcome

  • Streamlined clinical trial workflows through Site Lab Navigator e-Requisition innovation

Companies that use Nexelis

Customer profile

Segments3 records

Ideal customer profiles2 records

Nexelis technology and API

Technology

Technology focussed No

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Integration1 record

AI capability3 records

Feature2 records

Nexelis partnerships and signals

Strategic signal

Partnerships

One partnership is on record.

  • OracleBiocoreTechnology or IntegrationStrategic collaboration to advance AI-driven digital pathology. IQVIA Laboratories integrates OracleBio's advanced AI image analysis capabilities to enhance digital pathology workflows and improve clinical insights for customers.

Scale indicators1 record

Recent moves2 records

Expansion highlights2 records

Nexelis competitors and assessment

Company assessment

Direct peers

  • ICON plc (ICON Central Laboratories): ICON operates a global central laboratory network providing biomarker, bioanalytical, and specialty testing for clinical trials — directly overlapping Nexelis's core central lab and specialty biomarker services for pharma/biotech sponsors.
  • Fortrea (formerly Labcorp Drug Development): Fortrea is a leading CRO with a large central laboratory business spun out of Labcorp; it competes directly with Nexelis on global central lab, bioanalytical, and specialty biomarker services for clinical development.
  • Charles River Laboratories: Charles River provides research models, safety assessment, and laboratory services including bioanalytical and biomarker work for pharma and biotech — directly comparable to Nexelis's discovery, bioanalytical, and vaccine lab service offerings.
  • BioAgilytix Labs: BioAgilytix is a specialized bioanalytical and biomarker CRO serving large and small molecule drug developers — directly comparable to Nexelis's bioanalytical and biomarker services targeting the same biopharma customer base.
  • Q² Solutions: Q² Solutions is a clinical trial laboratory services joint venture with global central lab and biomarker capabilities, directly competing with Nexelis in central lab, genomics, and specialty biomarker testing for clinical development.
  • Frontage Laboratories: Frontage provides bioanalytical, CMC, and clinical laboratory services to pharma and biotech — directly comparable to Nexelis's bioanalytical and biomarker offerings with overlapping small/large molecule and biomarker testing capabilities.
  • Syneos Health (now private): Syneos Health was a global CRO with clinical and bioanalytical laboratory capabilities serving pharma/biotech, directly comparable to Nexelis's clinical development and lab services scope before its take-private transaction.

Broad incumbents

  • PPD (Thermo Fisher Scientific): PPD, the clinical research services arm of Thermo Fisher, offers global central laboratory and bioanalytical services as part of a much broader life sciences tools and CRO platform — directly competing with Nexelis at the lab services layer.
  • Eurofins Scientific: Eurofins is a global laboratory services group with deep pharma/biopharma testing and bioanalytical capabilities across central labs and specialty assays, competing for many of the same clinical trial and discovery sciences engagements as Nexelis.
  • Medpace: Medpace is a mid-sized clinical CRO operating its own central laboratory and supporting services for biopharma sponsors, representing a directly comparable operational model to Nexelis with broader therapeutic and geographic reach.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat2 records

Key risks5 records

Key highlights6 records

Customer concentration

Nexelis social profiles

Digital presence

Nexelis financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Nexelis leadership team

Management profile

Number of profiles

Profiles3 records

Nexelis funding detail

Funding detail

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Nexelis M&A and investment

M&A and investment

M&A2 records

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Nexelis

What does Nexelis do?

Nexelis is a specialty contract research organization that develops and validates bioanalytical, immunogenicity, and vaccine assays, then performs advanced laboratory testing on behalf of pharmaceutical and biotechnology sponsors. The offering spans assay development, method validation, and clinical-sample testing across immunology-focused programs, with depth reinforced by the AIT Bioscience bioanalytical and ImmunXperts immunology acquisitions.

Is Nexelis a public or private company?

Nexelis is a private company. It is classified as private equity controlled and is currently operating.

When was Nexelis founded?

Nexelis was founded in 1989. It employs 101 to 250 people.

Where is Nexelis based?

Nexelis is headquartered in Seattle, United States, in the North America region.

How does Nexelis make money?

One revenue line is on record: laboratory Services.

Who are Nexelis's main competitors?

Direct peers on record are ICON plc (ICON Central Laboratories), Fortrea (formerly Labcorp Drug Development), Charles River Laboratories, BioAgilytix Labs, Q² Solutions, Frontage Laboratories and Syneos Health (now private). Broad incumbents are PPD (Thermo Fisher Scientific), Eurofins Scientific and Medpace.

Does Nexelis have an API?

No public API is recorded for Nexelis.

What industry is Nexelis in?

Nexelis's product category is Clinical Laboratory Services. Its primary akta.pro industry code is HLAGAEAJ, Companion Diagnostics (CDx) Development & Trial Testing Support, with a secondary code of HLAGADAA, Bioanalytical Testing (PK/ADA/NAb). Its NAICS code is 621511 and its SIC code is 8071.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
BioXconomyAmpersand backs Belgian CRO P95 BV with eye on expansionAmpersand has completed a majority recapitalization of Belgian clinical research organization P95 BV to fund its expansion in vaccine and infectious disease services. As part of the transaction, Benoit Bouche, former CEO of Ampersand portfolio company Nexelis, will join P95 as chairman to support growth initiatives.PR NewswireBioanalytical Testing Services Market Worth $7.65 Billion by 2030: Grand View Research, Inc.Grand View Research released a market report projecting the global bioanalytical testing services market to reach $7.65 billion by 2030, growing at a CAGR of 8.6%, driven by increased outsourcing of R&D by biopharmaceutical companies and accelerated demand from COVID-19 vaccine production. In February 2021, Nexelis acquired GlaxoSmithKline's GCLP-certified clinical bioanalytical laboratory in Marburg, Germany, to enhance its vaccine production capacity. North America held the largest regional market share in 2021, while the Asia Pacific region is projected to register the fastest growth through 2030.PR NewswireCGI helps Nexelis gain a competitive advantage through digitization of business and IT workflowsCGI signed a full managed IT services contract with Nexelis, an international life sciences firm, to support Nexelis' digital transformation over a three-year period. Under the agreement, CGI will deliver managed security services, core IT infrastructure management, and enterprise application services, with initial priorities being the upgrade and international rollout of Infrastructure Managed Services and a Laboratory Information Management System. The partnership is aimed at enabling Nexelis to focus on its core scientific work while gaining a competitive advantage through IT modernization and workflow digitization.PR NewswireNexelis acquires the GSK vaccines clinical bioanalytical laboratory located in Marburg - Germany and enters into a 5-year strategic agreement with GSKNexelis, a portfolio company of Ampersand Capital Partners, has acquired GSK's GCLP-certified clinical bioanalytical laboratory in Marburg, Germany, along with approximately 80 scientists and analysts, under a 5-year strategic collaborative agreement. The transaction enables Nexelis to expand its global footprint and high-throughput clinical testing capacities in immunology and vaccine development. Nexelis intends to quickly expand the Marburg site and leverage the acquired capabilities to develop synergies across its North American and European sites.PR NewswireNexelis Acquires Integrated Bioanalytical CRO AIT BioscienceNexelis, a portfolio company of Ampersand Capital Partners, has acquired AIT Bioscience, an integrated bioanalytical laboratory based in Indianapolis, Indiana. This is Nexelis's fourth acquisition since 2018 and adds large molecule mass spectrometry capabilities to its service portfolio. The deal supports Nexelis's continued expansion strategy, which included acquiring Belgium-based ImmunXperts in March 2020 and establishing strategic partnerships for COVID-19 vaccine development.PR NewswireNexelis to Acquire Specialty Immunogenicity and Immune-Oncology Testing Laboratory ImmunXpertsNexelis, a portfolio company of Ampersand Capital Partners and a leading provider of assay development and laboratory testing, has signed a definitive agreement to acquire ImmunXperts, a specialty laboratory focused on immunogenicity and immuno-oncology in vitro functional and potency assays based in Gosselies, Belgium. The transaction, expected to close by the end of March 2020, will integrate ImmunXperts' expertise into Nexelis as a European hub and provide the combined entity with expanded high-throughput platform capabilities to support pharmaceutical and biotech clients across clinical trials. ImmunXperts' co-founders, CTO Sofie Pattijn and CEO Thibault Jonckheere, will continue in senior leadership roles at Nexelis following the acquisition.PR NewswireAnnouncing Nexelis, a new name with long experience in the world of immuno-scienceThree affiliated companies—NEOMED-LABS, Pacific Biomarkers, and PAIRimmune—officially launched under the unified brand name Nexelis on September 23, 2019, consolidating their global operations to enhance internal collaboration. The newly formed entity is a leading provider of assay development and specialty laboratory testing, having supported FDA filings for nearly 100 new molecular entities including blockbuster vaccines and large molecules. The merged company positions itself to offer clients expedited development timelines through its combined scientific expertise and advanced technology platforms.